241 related articles for article (PubMed ID: 28582432)
1. In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.
Wang J; Chandrasekhar V; Abbadessa G; Yu Y; Schwartz B; Kontaridis MI
PLoS One; 2017; 12(6):e0178905. PubMed ID: 28582432
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.
Marin TM; Keith K; Davies B; Conner DA; Guha P; Kalaitzidis D; Wu X; Lauriol J; Wang B; Bauer M; Bronson R; Franchini KG; Neel BG; Kontaridis MI
J Clin Invest; 2011 Mar; 121(3):1026-43. PubMed ID: 21339643
[TBL] [Abstract][Full Text] [Related]
3. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
Schramm C; Fine DM; Edwards MA; Reeb AN; Krenz M
Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H231-43. PubMed ID: 22058153
[TBL] [Abstract][Full Text] [Related]
4. Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines.
Yi JS; Perla S; Enyenihi L; Bennett AM
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32584792
[TBL] [Abstract][Full Text] [Related]
5. Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines.
Roy R; Krenz M
J Mol Cell Cardiol; 2017 Nov; 112():83-90. PubMed ID: 28911943
[TBL] [Abstract][Full Text] [Related]
6. Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines.
Yi JS; Perla S; Huang Y; Mizuno K; Giordano FJ; Vinks AA; Bennett AM
Cardiovasc Drugs Ther; 2022 Aug; 36(4):589-604. PubMed ID: 33689087
[TBL] [Abstract][Full Text] [Related]
7. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
Schramm C; Edwards MA; Krenz M
J Biol Chem; 2013 Jun; 288(25):18335-44. PubMed ID: 23673659
[TBL] [Abstract][Full Text] [Related]
8. Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.
Lauriol J; Cabrera JR; Roy A; Keith K; Hough SM; Damilano F; Wang B; Segarra GC; Flessa ME; Miller LE; Das S; Bronson R; Lee KH; Kontaridis MI
J Clin Invest; 2016 Aug; 126(8):2989-3005. PubMed ID: 27348588
[TBL] [Abstract][Full Text] [Related]
9. Elevated Ca2+ transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan syndrome with multiple lentigines.
Clay SA; Domeier TL; Hanft LM; McDonald KS; Krenz M
Am J Physiol Heart Circ Physiol; 2015 May; 308(9):H1086-95. PubMed ID: 25724491
[TBL] [Abstract][Full Text] [Related]
10. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
[TBL] [Abstract][Full Text] [Related]
11. Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog.
Hahn A; Lauriol J; Thul J; Behnke-Hall K; Logeswaran T; Schänzer A; Böğürcü N; Garvalov BK; Zenker M; Gelb BD; von Gerlach S; Kandolf R; Kontaridis MI; Schranz D
Am J Med Genet A; 2015 Apr; 167A(4):744-51. PubMed ID: 25708222
[TBL] [Abstract][Full Text] [Related]
12. LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.
Ishida H; Kogaki S; Narita J; Ichimori H; Nawa N; Okada Y; Takahashi K; Ozono K
Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1531-9. PubMed ID: 21803945
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis of multiple lentigines in LEOPARD syndrome with PTPN11 gene mutation.
Motegi S; Yokoyama Y; Ogino S; Yamada K; Uchiyama A; Perera B; Takeuchi Y; Ohnishi H; Ishikawa O
Acta Derm Venereol; 2015 Nov; 95(8):978-84. PubMed ID: 25917897
[TBL] [Abstract][Full Text] [Related]
14. Investigating the reason for loss-of-function of Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) caused by Y279C mutation through molecular dynamics simulation.
Liu WS; Wang RR; Li WY; Rong M; Liu CL; Ma Y; Wang RL
J Biomol Struct Dyn; 2020 Jun; 38(9):2509-2520. PubMed ID: 31258001
[TBL] [Abstract][Full Text] [Related]
15. mTOR pathway in human cardiac hypertrophy caused by LEOPARD syndrome: a different role compared with animal models?
Cui H; Song L; Zhu C; Zhang C; Tang B; Wang S; Wu G; Zou Y; Huang X; Hui R; Wang S; Wang J
Orphanet J Rare Dis; 2019 Nov; 14(1):252. PubMed ID: 31722741
[TBL] [Abstract][Full Text] [Related]
16. Low-dose dasatinib rescues cardiac function in Noonan syndrome.
Yi JS; Huang Y; Kwaczala AT; Kuo IY; Ehrlich BE; Campbell SG; Giordano FJ; Bennett AM
JCI Insight; 2016 Dec; 1(20):e90220. PubMed ID: 27942593
[TBL] [Abstract][Full Text] [Related]
17. Genotype-phenotype association by echocardiography offers incremental value in patients with Noonan Syndrome with Multiple Lentigines.
Kauffman H; Ahrens-Nicklas RC; Calderon-Anyosa RJC; Ritter AL; Lin KY; Rossano JW; Quartermain MD; Banerjee A
Pediatr Res; 2021 Aug; 90(2):444-451. PubMed ID: 33318624
[TBL] [Abstract][Full Text] [Related]
18. Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.
Yu Y; Savage RE; Eathiraj S; Meade J; Wick MJ; Hall T; Abbadessa G; Schwartz B
PLoS One; 2015; 10(10):e0140479. PubMed ID: 26469692
[TBL] [Abstract][Full Text] [Related]
19. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
